Generic drugs make up about 80% of the market in Russia. On average, there are about 10 generics per original drug in addition to around 3050 generics for antibiotics and painkillers. Given the decrease in the supply of finished dosage forms from European countries, generics are becoming the main alternative drug on the Russian market, while the risks of drug defects due to sanctions are protected by the law on the compulsory licensing of medicines. However, the main keys to strengthening the Russian pharmaceutical market should not only be independence from imports, but also the development of the countrys own innovations. Russia needs to create a cluster of enterprises that are capable of synthesizing active pharmaceutical ingredients, and conditions should be created to develop an innovative pharmaceutical industry. What regulatory policy and quality control solutions are needed to create competitive generics in Russia? Do domestic pharmaceutical manufacturers have enough capacity and technology to develop generics for drugs that are covered by the law on compulsory licensing? What state support instruments for R&D will help stimulate the development of the innovative pharmaceutical industry in Russia? What new models of cooperation do business and scientific development institutions need to develop and introduce to stimulate innovation in the pharmaceutical and biotechnology market?